(The Center Square) – Wisconsin is set to give Eli Lilly up to $100 million in Enterprise Zone tax credits for its $3 billion expansion in Bristol announced last year.
Eli Lilly plans to add 750 jobs at the expanded facility in addition to the 130 current employees.
The expansion will be used to expand the medical supply company’s injectable manufacturing for diabetes, obesity and future medicines.
The original 84,000-square foot facility was completed for Nexus Pharmaceuticals in 2021 after the $100 million facility was first announced in 2019 along with $1.5 million in state tax credits.
“Together, we’re advancing innovative manufacturing capabilities, building capacity for the medicines of tomorrow, creating high-quality jobs, and ensuring that patients here and around the world have access to life-changing treatments,” Executive Vice President and President of Lilly Manufacturing Operations Edgardo Hernandez said in a statement. “We look forward to contributing to the region’s strong legacy of innovation and economic vitality for years to come.”
Eli Lilly plans to use automation, including guided vehicles, robotics, and production equipment, at the expanded facility.
Digital automation will be embedded throughout the site to accelerate processes and increase accuracy, the company said.
“This project represents not just a major step forward for the company and its manufacturing capacity, but for the future of our state as a global leader in the field of biohealth and biopharmaceuticals,” said WEDC Secretary and CEO Missy Hughes.
